Sylvie Rottey - Concepedia

Author

Sylvie Rottey

Ghent University Hospital ORCID

Also Known As

A Bessudo, F. Duprez, ROTTEY S, ROTTEY S, Rottey Sylvie, Rottey, S., Rottey, Sylvie, S Rottey, S. ROTTEY, S. Rottey

557

Publications

12K

Citations

H-Index

102

Concepts

All Affiliations

Ghent University Hospital Antwerp University Hospital Cliniques Universitaires Saint-Luc Institut Jules Bordet Institut Gustave Roussy

About

Sylvie Rottey is an author at Ghent University Hospital specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	26	52	3.1K
2	Health Sciences	7	7	298
3	Engineering	1	1	10
4	Natural Sciences	1	1	31
5	Biochemistry	1	1	31

Sylvie Rottey

116

Publications

10.2K

Citations

H-Index

Page 1

	Year	Citations
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer Jan B. Vermorken, Fernando Rivera, Éva Remenár, New England Journal of Medicine	2008	3.7K
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study Udai Banerji, Carla M.L. van Herpen, Cristina Saura, The Lancet Oncology Breast OncologyHer2-expressing Breast CancerMedicinePharmacologyTrastuzumab Duocarmazine	2019	549
Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib Axel Bex, Peter F.A. Mulders, Michael A.S. Jewett, JAMA Oncology	2018	468
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial Jan B. Vermorken, Jan Stöhlmacher-Williams, Lisa Licitra, The Lancet Oncology Metastatic Squamous-cell CarcinomaOpen-label Phase 3MedicinePathologyHead And Neck Cancer	2013	432
Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma Thomas E. Hutson, Ian D. Davis, Jean‐Pascal Machiels, Journal of Clinical Oncology	2009	292
Distant metastases in head and neck cancer Fréderic Duprez, Dieter Berwouts, Wilfried De Neve, Head & Neck	2017	241
Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study Lisa Licitra, Fernando Rivera, Éva Remenár, Annals of Oncology MedicinePathologyExtreme StudyFirst-line TreatmentHead And Neck Cancer	2010	229
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study Shubham Pant, Martin Schüler, Gopa Iyer, The Lancet Oncology Fgfr AlterationsMedicinePathologyAdvanced Solid TumoursFibroblast Growth Factor	2023	175
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial Jean‐Pascal Machiels, Yungan Tao, Lisa Licitra, The Lancet Oncology Concurrent ChemoradiotherapyNeoadjuvant TherapySquamous Cell CarcinomaMedicineHead And Neck Cancer	2024	174
Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck Fernando Rivera, Andrzej Kawecki, Sylvie Rottey, Annals of Oncology	2010	129

Page 1